Shares of Novavax Inc. NVAX slid 3.09% to $7.83 Wednesday, on what proved to be an all-around mixed trading session for the ...

Novavax Inc. closed 66.14% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%. 1/31 weekly 10 calls and 1/31 weekly 9.5 calls are ...

Novavax (NVAX) ended the recent trading session at $8.55, demonstrating a +0.53% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.83% ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...